


ECLAT-Endometrial Cancer Lymphadenectomy Trial

AGO-OP.6



- **histologically confirmed endometrial cancer**
- **FIGO IB or FIGO II (all subtypes)**
- **FIGO IA, G3 (Type I)**
- **FIGO IA (Type II)**
- **Absence of bulky nodes**
- **Age 18 - 75y**



n=640

System. lymphadenectomy

- **pelvic**
- **para-aortic**

no lymphadenectomy

Primary endpoint: Overall Survival

Type I: endometrioid, endometrioid + squamous differentiation, mucinous

Type II: serous, clear cell, carcinosarcoma

SLN in LNE arm as additional procedure allowed

ECLAT-Endometrial Cancer Lymphadenectomy Trial

AGO-OP.6



- Randomized Phase III trial, prospective, multicenter
- Coordinating investigator: Günter Emons
- Sponsor: Philipps-University Marburg / AGO Study Group
- Planned number of patients: 640 pts. in 5 years
- Current accrual: 31 pts randomized (status on 24 Sep 2018)